Manufacture of Biological Active Substances and Medicinal Products for Human Use
Provides GMP requirements specific to biological active substances and medicinal products, covering cell banking, seed lot systems, containment of adventitious agents, and the additional controls required for biological processes.
What this does not cover
stated in the document's own scope- Covers biological active substances and medicinal products for human use; equivalent expectations for veterinary biologicals sit in the veterinary framework.
- Supplements the main EU GMP Guide with biological-specific controls; it does not replace the general GMP chapters, which still apply.
- Addresses biological manufacturing, not the sterile-processing controls that Annex 1 provides where the product is also sterile.
- Sets GMP for the substance and product, not the clinical evaluation or market authorisation, which follow their own EU pathways.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
EU GMP Annex 2, "Manufacture of Biological Active Substances and Medicinal Products for Human Use", supplements the main EU GMP Guide with the additional controls that biological processes need. It covers the special features of working with living systems — biological variability, the use of seed lots and cell banks, and the risk of adventitious agents — and applies across a broad range of product types, from vaccines and blood/plasma products to biotechnology-derived proteins, gene-therapy and cell-based products. It pairs a principles section with a product-specific part, so a manufacturer reads the general biological expectations alongside the guidance for its particular class of product.
Scope & applicability
Manufacturers of biological active substances and biological medicinal products including vaccines, monoclonal antibodies, and plasma-derived products. Advanced therapy medicinal products (ATMPs) are excluded — they are covered by the dedicated Part IV ATMP GMP guideline.
Legal basis & how it acquires force
Annex 2 sits in Volume 4 of EudraLex, the EU GMP Guide, and interprets the GMP requirements of the EU GMP Directives as they apply to biological medicines. It is guidance rather than stand-alone law, but adherence is a condition of the manufacturing authorisation. The current version applied from 31 January 2013. It is read together with the main guide and with the parts of the EU regulatory framework governing advanced-therapy and blood/tissue-derived products, which carry their own additional legal requirements.
Document structure
| Part | Covers |
|---|---|
| Scope and principle | The product types covered and the special GMP considerations for biological materials |
| Seed lot and cell bank system | Master and working seed lots and cell banks, their characterisation and control |
| Premises, equipment and containment | Facility design and the containment measures for handling live organisms |
| Prevention of adventitious contamination | Risk-based control of adventitious agents throughout the process |
| Starting and raw materials | Sourcing, qualification and control of biological starting and raw materials |
| Product-specific guidance | Additional expectations for vaccines, blood/plasma, biotech, gene-therapy and cell-based products |
Key requirements
- Two-tier cell banking system with full characterisation of master cell bank (MCB) and working cell bank (WCB)
- Adventitious agent testing programme covering viral, mycoplasma, and bacteriophage contamination
- Segregation and containment strategies for organisms with different containment requirements
- Seed lot systems for fermentation/culture processes
- Closed process design where possible; containment strategy for open steps
Implementation tips
- Cell bank characterisation is a long-lead activity — plan 12-18 months for full testing programme
- Containment strategy document should be aligned with the CCS (Annex 1) for facilities doing sterile biologics
Revision notes
Current version came into operation 31 January 2013 (restructured GMP guide; broader biological product scope). ATMPs were subsequently carved out to the standalone Part IV ATMP GMP guideline.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Annex 2 aligns with the ICH biotechnology-quality guidelines — notably Q5A on viral safety, Q5D on cell substrates, and Q6B on specifications — which underpin its cell-bank and adventitious-agent expectations. It complements Annex 1 where a biological product is also sterile, and it is the EU counterpart to the biologics-specific GMP expectations FDA applies under 21 CFR Parts 600–680.
EU GMP Annex 2: frequently asked questions
Quick answers to common questions about EU GMP Annex 2.
What products does EU GMP Annex 2 cover?
Annex 2 covers biological active substances and medicinal products for human use — including vaccines, blood and plasma products, biotechnology-derived proteins, and advanced therapies such as gene-therapy and cell-based products — setting the additional GMP controls those processes require.
What is the seed lot and cell bank system in Annex 2?
It is the two-tier system of master and working seed lots or cell banks used to keep biological starting material consistent over a product’s life. Annex 2 sets expectations for how these banks are established, characterised and controlled.
When did the current Annex 2 apply?
The current version of Annex 2 came into operation on 31 January 2013. It is read together with the main EU GMP Guide and, where relevant, Annex 1 for sterile biological products.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.